Identification of a novel, methylation-dependent, <em>RUNX2</em> regulatory region associated with osteoarthritis risk by Rice SJ et al.
Human Molecular Genetics, 2018, Vol. 00, No. 00 1–11
doi: 10.1093/hmg/ddy257
Advance Access Publication Date: 10 August 2018
General Article
G EN E RA L ART I C L E
Identification of a novel, methylation-dependent,
RUNX2 regulatory region associated with
osteoarthritis risk
Sarah J. Rice1,*, Guillaume Aubourg1, Antony K. Sorial1, David Almarza1,
Maria Tselepi1, David J. Deehan2, Louise N. Reynard1 and John Loughlin1,*
1Skeletal Research Group, Institute of Genetic Medicine, Newcastle University, International Centre for Life,
Newcastle upon Tyne, NE1 3BZ, UK and 2Newcastle University Teaching Hospitals NHS Trust, Freeman
Hospital, High Heaton, Newcastle upon Tyne, NE1 7DN, UK
*To whom correspondence should be addressed at: Institute of Genetic Medicine, Newcastle University, International Centre for Life, Newcastle upon
Tyne, NE1 3BZ, UK. Tel: +44 191 241 8988; Fax: +44 191 241 8666; Email: sarah.rice@ncl.ac.uk and john.loughlin@ncl.ac.uk
Abstract
Osteoarthritis (OA) is a common, multifactorial and polygenic skeletal disease that, in its severest form, requires joint
replacement surgery to restore mobility and to relieve chronic pain. Using tissues from the articulating joints of 260 patients
with OA and a range of in vitro experiments, including CRISPR-Cas9, we have characterized an intergenic regulatory element.
Here, genotype at an OA risk locus correlates with differential DNA methylation, with altered gene expression of both a
transcriptional regulator (RUNX2), and a chromatin remodelling protein (SUPT3H). RUNX2 is a strong candidate for OA
susceptibility, with its encoded protein being essential for skeletogenesis and healthy joint function. The OA risk locus
includes single nucleotide polymorphisms (SNPs) located within and flanking the differentially methylated region (DMR).
The OA association SNP, rs10948172, demonstrates particularly strong correlation with methylation, and two intergenic SNPs
falling within the DMR (rs62435998 and rs62435999) demonstrate genetic and epigenetic effects on the regulatory activity of
this region. We therefore posit that the OA signal mediates its effect by modulating the methylation of the regulatory
element, which then impacts on gene expression, with RUNX2 being the principal target. Our study highlights the interplay
between DNA methylation, OA genetic risk and the downstream regulation of genes critical to normal joint function.
Introduction
Osteoarthritis (OA) is an age-related, complex disease char-
acterized by the irreversible breakdown of articular cartilage,
most commonly in the hip or knee (1). Under non-pathological
conditions, articular cartilage facilitates joint function by
minimizing friction and bearing the impact of mechanical
loading (2). Loss of this cartilage is painful and, ultimately,
debilitating. Current therapeutic intervention relies initially
on symptomatic pain relief and replacement of the affected
joint in end-stage disease (3). Genetic risk factors confer
50% of disease susceptibility and, to date, genome-wide
association studies (GWAS) have reported up to 30 risk loci
for OA (https://www.nature.com/articles/s41588-018-0079-y).
Functional correlations have been established between genetic
risk and epigenetic variation, principally via DNA methylation
changes at CpG sites (4).
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The common single nucleotide polymorphism (SNP)
rs10948172 (A/G) has been associated with increased OA
susceptibility in the UK GWAS arcOGEN study (P = 7 x 10−8)
(5). This variant marks a region of 570 kb of high linkage
disequilibrium (LD) at chromosome 6p21.1, containing the genes
SUPT3H and RUNX2. These genes are transcribed in opposite
directions and overlap at their 5′ ends. SUPT3H encodes a protein
subunit of the transcription initiation complex STAGA, a histone
acetyltransferase that preferentially acetylates histone 3 (H3)
(6). RUNX2 is a transcription factor essential for osteoblastic
differentiation and skeletogenesis and has two main isoforms,
encoded by distal (P1) and proximal (P2) promoter regions
(7). Murine studies have shown regulation of Runx2 gene
expression by the promoter region of Supt3h during osteoblastic
differentiation (8).
We have previously reported the results of a genome-
wide methylation analysis of cartilage DNA using the Illumina
Infinium Human Methylation 450 BeadChip array (450K array)
(9,10). We observed correlation between genotype at rs10948172
and methylation at seven CpGs located close to SUPT3H
and RUNX2, four 450K array CpGs (cg13979708, cg19254793,
cg20913747 and cg18551225) and three CpGs that were captured
using pyrosequencing (9). This cluster of seven CpGs are located
82 kb upstream of rs10948172, with the OA risk-conferring G
allele of the SNP significantly correlating with reduced levels
of methylation at each CpG (9). Together, these seven CpGs
constitute a methylation quantitative trait locus (mQTL) and
form a differentially methylated region (DMR), which will be
referred to henceforth as the SUPT3H/RUNX2-DMR. Additional
analysis revealed that this DMR was also present in two other
joint tissues from OA patients: synovium and infrapatellar fat
pad (9). None of the published epigenome-wide studies of OA
cartilage have identified differential methylation at the four
450K array CpG sites in this DMR (10–14). These studies have
considered methylation between OA and non-OA cartilage,
intact and lesioned cartilage from the same joint and also
amongst different regions of the tibial plateau. This indicates
that differential methylation in this region is being driven by
genotype and not disease state.
Two further GWAS reported that the SNP rs10948155 (T/C),
which resides 89 kb upstream of rs10948172, correlates with the
OA endophenotype of cartilage thickness (15,16). rs10948155 and
rs10948172 flank the SUPT3H/RUNX2-DMR and have a pairwise r2
of 0.70 in Europeans. As such, they may be marking the same
OA association signal. Furthermore, the SUPT3H/RUNX2-DMR
contains two common SNPs, rs62435998 (C/T) and rs62435999
(T/G), that are in perfect LD with each other (r2=1.0) and in
high LD with rs10948155 (r2=0.87) and rs10948172 (r2=0.80). In
summary, there are two reported SNPs that correlate with OA
phenotypes and that flank the SUPT3H/RUNX2-DMR and two
SNPs that also correlate with these OA signals and reside within
the DMR.
In this study, we set out to undertake a detailed molecular
characterization of the SUPT3H/RUNX2-DMR and to investigate
its regulatory effect on SUPT3H and RUNX2. We aimed to
define the 5′ and 3′ limits of the DMR and to investigate the
effect of SNP genotype upon methylation. We also searched
for expression quantitative trait loci (eQTLs) at SUPT3H and
RUNX2, and looked for correlations between mQTLs and
eQTLs to establish the presence of methylation and eQTLs
(meQTLs). Finally, using CRISPR-Cas9 and luciferase analysis,
we determined the effect of DMR deletion on SUPT3H and
RUNX2 expression and of in vitro methylation on the activity of
the DMR.
Results
In silico investigation into the SUPT3H-RUNX2 DMR
We previously identified seven CpG sites that correlate with
rs10948172 genotype in OA patients (9). These reside within and
on the south shore of a CpG island located 82 kb upstream of
the OA association SNP rs10948172 (Fig. 1A and B). Our search of
the University of California Santa Cruz (UCSC) Genome Browser
and the Roadmap Epigenomics Project revealed that this DNAseI
hypersensitive region is marked as a weak enhancer in multi-
ple cell types, including MSCs and MSC-derived chondrocytes
(Fig. 1B). This is indicated by the presence of weak H3K27ac
peaks, along with signals for H3K36me3 in the 18-state model.
Analysis of the 15-statemodel revealed peaks for H3K4me1, sug-
gesting that this region is a poised enhancer in these cell types
(17). Furthermore, this region is highly conserved in primates but
is absent from the genome of quadrupedal mammals (data not
shown).
Additional ENCODE ChIP-seq data revealed binding sites
within the DMR for the transcription factors in the GM12872
lymphoblastoid cell line: NFATC1, PXB3, BCL3 and TCF3 (Fig. 1B).
Physical limits of the SUPT3H/RUNX2-DMR
We next used pyrosequencing analysis to determine the 5′ and
3′ physical limits of the DMR in OA patient DNA samples. We
have previously reported that theDMRhad a stronger correlation
with rs10948172 genotype in synovium than cartilage (9) and
we therefore used OA synovium DNA samples to determine its
maximal limits. In our analysis, we included the four positive
CpGs from the 450k array (CpGs 7–10 in Table S1) plus six
CpGs upstream (CpG1–CpG6) and five CpGs downstream (CpG11–
CpG15), spanning a region of 808 bp. All CpG sites within the
investigated region are schematically represented in Figure 1C.
The 15 CpG sites analysed in this study are highlighted.
A significant synoviummQTL (P<0.05) relative to genotype at
rs10948172was detectable at 11 of the 15 sites (Fig. 2). The 5′ limit
of the DMR was determined exactly; an mQTL was detectable
at CpG2 (P<0.0001) but not at CpG1 (P=0.12), with no further
CpGs between the two. Analysis of the 3′ limit proved technically
challenging due to the high density of CpG sites in this region
(Fig. 1C). However, the three CpGs captured by assay 8 (CpG13–
CpG15) showed no significant mQTL (P>0.05, Fig. 2), and as such
the DMR extends from CpG2 up to, but not including, CpG13, a
region of 572 bp.
We subsequently assessed the limits of the DMR in cartilage
and fat pad DNA (Figs. S1 and S2), again relative to genotype at
rs10948172. In these tissues,no significantmQTLwas detected at
CpG2, which informed us that we had defined the 5′ limit of the
DMR. Therefore, analysis of CpG1 was not undertaken in these
tissues. In total, we analysed 14 of the 15 CpGs that have been
studied in our synoviumDNAs, CpG2–CpG15.A significantmQTL
was observed at CpGs 6–12 in cartilage and CpGs 3–12 (with the
exception of CpG 6) in fat pad.
Finally, we investigated the existence of the SUPT3H/RUNX2-
DMR in trabecular bone DNA from patients with OA, a tissue not
previously studied. Due to the relatively modest sample size of
up to 31 bone samples, only two homozygotes for the OA risk-
conferring G allele of rs10948172 were identified (Table S2). We
therefore measured the effect of the risk allele by comparing AA
homozygotes to those carrying one or two copies of the risk allele
(AG/GG) (Fig. S3). Two of the 14 CpGs showed a significant mQTL:
CpG 7 and CpG 11.
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Figure 1. In silico investigation of the SUPT3H/RUNX2-DMR. (A) Chromosome 6p21.1 visualized using the Integrative Genomics Viewer displaying the location of the four
SNPs and of the CpGs investigated relative to the SUPT3H, RUNX2 (P1 isoform) and RUNX2 (P2 isoform) transcripts. The region represented is indicated by the red box on
the chromosome diagram. Arrows indicate the direction of transcription. (B) Zoomed-in image (red vertical line on chromosome) showing the location of the 15 CpGs
analysed (1), the CpG island denoted on UCSC (2), the transcription factor binding sites (NFATC1, PBX3, BCL3 and TCF3) and (4) ROADMAP ChIP-seq data in three different
cell types displaying peaks in this region. Yellow: weak enhancer, green: weak transcription, red: flanking transcription start site (TTS). Data are interpreted using the
18-state model. (C) Schematic representation of the 808 bp region in which the 15 investigated CpGs (solid black circles) reside. Open circles represent un-investigated
CpGs. Vertical red lines mark the location of rs62435998 and rs62435999.
In summary, the DMR was active across four joint tissues
from patients with OA andwas narrowed to amaximum interval
of 572 bp in synovium.
The effect of genotype upon methylation within
the SUPT3H/RUNX2-DMR
We subsequently determined the extent to which genotype at
the OA association SNPs rs10948172 and rs10948155, and at the
DMR SNPs rs62435998 and rs62435999, influencesmethylation in
this region. Since rs62435998 and rs62435999 are in perfect LD,
we only genotyped one of these SNPs (rs62435998).
Using samples that had a complete data set of matched
methylation and genotype data, we constructed a linear model
of the percentage methylation at the individual sites assessing
the relative contribution of each SNP to differential methylation.
We then constructed a heat map of the percentage genotypic
effect at each CpG site in all four investigated OA joint tissues
(Fig. 3). In total, we had complete data available for 59 synovium,
30 cartilage, 44 fat pad and 25 bone DNA samples.
The strongest mQTL was detected in synovium, followed by
cartilage, fat pad and then bone. In synovium, the strongest
effect was at CpG9, with genotype at all three SNPs combined
accounting for 65.79% of variability in methylation. The vast
majority of this genotypic effect was explained by genotype
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Figure 2. Definition of the 5′ and 3′ limits of the SUPT3H/RUNX2-DMR in OA synovium DNA. Graphs display the percentage methylation at each of the 15 CpG sites
stratified by genotype at the OA association SNP rs10948172 (A/G). P-values were calculated using a one-way analysis of variance (ANOVA) with a Bonferonni post-test
correction. The horizontal line represents the mean methylation and the standard error of the mean (SEM). n, the number of patients analysed per CpG.
Figure 3. The influence of genotype uponmethylation at the SUPT3H/RUNX2-DMR.Heatmap displaying the percentage effect of genotype at rs10948172, rs10948155 and
rs62435998, plus all three SNPs combined, at CpG2 to CpG12 in the following: (A) synovium (n = 59 patients), (B) cartilage (n = 30 patients), (C) fat pad (n = 44 patients)
and (D) bone (n = 25 patients). The relative contribution of each SNP was calculated using the log worth and incremental R2 statistics. The incremental improvement
in R2 values capturing explained variability was then plotted. Statistical analyses were performed with the aid of SAS JMP Statistical Data Visualization Software.
at rs10948172 (63.08%), with genotype at rs10948155 and
rs62435998 providing modest contributions (1.73% and 0.98%,
respectively). A broadly similar effect was observed at all CpG
sites analysed in synovium, with the exception being CpG6,
where only a weakmQTL was detected. These data indicate that
in synovium, genotype at rs10948155 and rs62435998 does not
function in coordinationwith rs10948172 to provide a haplotypic
effect.
In cartilage, the strongest effect was at CpG8, with genotype
at the three SNPs combined accounting for 54.62% of variability.
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Again, rs10948172 explained the majority of this effect, with a
contribution of 33.99%. However, here we observed more sub-
stantive contributions from rs10948155 and rs62435998. In fat
pad and bone, where weaker mQTLs were detected, less of the
variation in methylation was explained by genotype at all three
SNPs,withmeasured values of up to 26.86% in fat pad and 15.73%
in bone (Fig. 3).
Overall, this analysis highlighted that the arcOGEN SNP
rs10948172 is the principal driver of the observed differential
methylation, with particularly strong effects in both synovium
and cartilage.
Allelic expression imbalance analysis of SUPT3H
and RUNX2
We next used allelic expression imbalance (AEI) analysis to
measure rs10948172 eQTLs operating on SUPT3H and RUNX2. In
all four joint tissues, we identified an increase in expression
of the C allele of the SUPT3H transcript SNP rs529125, which
is equivalent to the OA risk-conferring G allele of rs10948172
(Fig. 4). The greatest imbalance was detected in bone samples,
with a mean increase of 2.2-fold (P=0.002, Fig. 4D). In the other
tissues, themean increaseswere 1.17-fold in synovium (P=0.023,
Fig. 4A), 1.15-fold in cartilage (P=0.0422, Fig. 4B) and 1.11-fold in
fat pad (P=0.001, Fig. 4C).A SUPT3H eQTL operating in association
with rs10948172 has been reported in 10 different tissues on the
genotype-tissue expression (GTEx) browser (18).
RUNX2 AEI was measured in all four joint tissues. Here,
the variance in compound heterozygotes was compared to that
measured in patients who were homozygotic at the OA associ-
ation SNP. Significant AEI was detected in synovium (P=0.034,
Fig. 5A), cartilage (P=0.0005, Fig. 5B) and fat pad (P=0.006, Fig. 5C)
but not in bone samples (Fig. 5D). Due to the linkage equilibrium
between rs10948172 and the RUNX2 transcript SNP rs1200428
(r2=0.005), it is not possible to determine the direction of the
RUNX2 AEI.
In summary, the AEI analysis demonstrated the presence of
an rs10948172 eQTL operating on both SUPT3H and RUNX2 in
multiple joint tissues.
The impact of the mQTL upon gene expression
of SUPT3H and RUNX2
Following the characterization of themQTL at the SUPT3H/RUNX2
locus and the identification of eQTLs operating on both SUPT3H
and RUNX2, we next set out to assess the presence of an meQTL.
To achieve this, we stratified the methylation values at the CpG
sites by the AEI ratios in patient samples for which matched
methylation and AEI data were available. We focused on the 11
CpGs that generated evidence of mQTLs in our earlier analysis,
CpG2–CpG12 (Fig. 2 and Figs. S1–S3).
For SUPT3H, we had observed AEI in all four tissues (Fig. 4),
but we did not observe any significant correlations between CpG
methylation and AEI ratio in any of the tissues when they were
analysed separately (data not shown).
Due to the linkage equilibrium between the RUNX2 transcript
SNP rs1200428 and rs10948172, it was necessary to assume that
all patient samples demonstrated AEI in the same direction for
this gene. Therefore, those samples with AEI ratios <1 were
inverted to provide a unidirectional imbalance in allelic expres-
sion. The meQTL analysis was then carried out in synovium,
cartilage and fat pad samples as they were the three tissues in
which RUNX2 AEI was detected (Fig. 5). Significant correlation
was observed in synovium at six CpGs (CpG7–CpG12) (Fig. 6). In
fat pad, a significant meQTL was observed at CpG4 (P=0.009),
with CpG12 approaching significance (Fig. S4A). No significant
meQTL was detected in cartilage (Fig. S4B). The absence of LD
between rs1200428 and rs10948172 precludes us from determin-
ing the direction of the relationship between methylation and
allelic expression of RUNX2.
Overall, this analysis revealed a significant correlation with
DMR methylation levels and the level of AEI of RUNX2 in syn-
ovium and fat pad but not cartilage. We observed no correlation
between methylation and SUPT3H AEI in any tissue analysed,
where the genetic and epigenetic effects appear to be function-
ing independently.
Functional analysis of SUPT3H/RUNX2-DMR
using CRISPR-Cas9
We next assessed the effect that deletion of the DMR had on
SUPT3H and RUNX2 expression. Using the chondrocyte cell line
Tc28a2 and the CRISPR-Cas9 genome editing system,we deleted
a 600 bp region that encompassed the 572 bp DMR that we had
defined. This had no effect on SUPT3H expression or on the
combined expression of both P1 and P2 RUNX2 isoforms (mea-
sured using the RUNX2ALL assay).However,when RUNX2 P1was
measured alone, a mean 3.9-fold increase in gene expression
was observed (P<0.005, Fig. 7A). These in vitro data support the
DMR as a regulator of RUNX2 expression.
Relationship between DMR methylation and its function
Finally, we investigated the effect of in vitro methylation on
the DMR. In this analysis, we also investigated any effect of
genotype at the two SNPs located within the DMR, rs62435998
and rs62435999. The common CT haplotype of rs62435998-
rs6243599 corresponds to the non-risk alleles of rs10948172
(A) and rs10948155 (T), whilst the TG haplotype corresponds
to the risk-conferring alleles of rs10948172 (G) and rs10948155
(C). Both haplotypes of the DMR were separately cloned into the
pCpGL luciferase vector (19) and analysed with and without in
vitro methylation. This vector contains no CpG sites, allowing
the effects of DMR methylation on luciferase activity to be
determined independent of any effects conferred by vector
methylation. The vectors were then transfected into the
chondrosarcoma cell line SW1353.
Without methylation, the non-risk CT construct showed
no difference in activity relative to the empty pCpGL vector,
whereas the risk-conferring TG construct showed a 3.2-
fold increase in luciferase activity (P<0.0001) (Fig. 7B). With
methylation, both constructs showed a significant increase
in activity: CT, 1.79-fold above control, P<0.01; TG, 8.24-fold
above control, P<0.001. These results demonstrate that the
SUPT3H/RUNX2-DMR displays transcriptional regulatory activity
in SW1353 cells and that methylation of the region enhances
this effect. The data also indicate that the risk haplotype is a
stronger regulator than the non-risk haplotype.
Discussion
Using DNA isolated from the joint tissues of patients with OA,
we were able to narrow the SUPT3H/RUNX2-DMR to a 572 bp
interval. To our knowledge, this is the first published study into
the physical limits of an OA-associated mQTL, reported here in
multiple tissues. The presence of this mQTL in multiple tissues
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Figure 4. AEI analysis of SUPT3H using the transcript SNP rs529125. AEI was carried out in OA patient samples from the following tissues: (A) synovium (n = 18 patients),
(B) cartilage (n = 8 patients), (C) fat pad (n = 13 patients) and (D) bone (n = 9 patients). Data for individual patients are plotted as the ratio of the risk C allele divided
by the non-risk T allele, with the cDNA ratio normalized to that measured in the DNA of the same patient sample. A ratio > 1 indicates an increased expression of the
risk C allele. Each patient DNA and cDNA sample was analysed in triplicate. X-axis lists the patient IDs. The mean DNA and cDNA values for all patients combined in
each tissue are displayed as a box plot denoting the median value, along with the 25th to 75th percentiles. Whiskers represent the 10th and 90th percentiles, and any
outliers are displayed. P-values were calculated using a two-tailed paired t-test.
of the articulating joint highlights the joint-wide pathology
of OA. In silico analysis of publicly available data revealed the
region as having transcriptional regulatory properties. ChIP-
seq data reveal that several cartilage-expressed transcription
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Figure 5. AEI analysis of RUNX2 using the transcript SNP rs1200428. AEI was
carried out in rs1200428 heterozygous OA patient samples from the following
tissues: (A) synovium (n = 13 patients), (B) cartilage (n = 22 patients), (C) fat
pad (n = 17 patients) and (D) bone (n = 12 patients). The ratio of G/T alleles was
determined in patient DNA and cDNA and each cDNA ratio was normalized to
thatmeasured in the DNA of the same patient sample. These data were stratified
by genotype at the association SNP, rs10948172. Each patient DNA and cDNA
samplewas analysed in triplicate and themean cDNA ratio per patient is plotted.
P-values were calculated using an unpaired t-test of variances. Horizontal lines
represent the mean values across patients.
factors bind to this region in the GM12872 cell line. Stratification
by genotype at OA-associated SNPs highlighted the arcOGEN OA
SNP rs10948172 as showing particularly strong correlation with
the methylation at the DMR. This was an important observation
as it suggests a mechanism by which this OA risk-conferring
signal mediates its effect, namely modulating methylation at
the DMR, which then alters gene expression at the allelic level
(Fig. S5). To determine whether this was plausible, we first
assessed whether SUPT3H and RUNX2 were subject to an
rs10948172 eQTL in OA tissues. Having determined that this
was the case for both genes, we were then able to show that
RUNX2AEI correlatedwithmethylation in synovium and fat pad,
revealing an meQTL. We next directly demonstrated that DMR
was a transcriptional regulator by deleting it in the Tc28a2 cell
line, observing altered expression of the P1 isoform of RUNX2.
This isoform is predominantly expressed in mesenchymal stem
cells through to chondrocyte progenitor cells and in mature
osteoblasts (20–22). We finally undertook in vitro analysis of
the DMR and we were able to show that both methylation and
haplotype directly regulated gene transcription. This supports
the functional mechanism posited in Supplementary Figure S5,
in that it clearly demonstrates that methylation of the DMR
alters gene expression. In this final experiment, we included
genotype at the two common DMR SNPs rs62435998 and
rs6243599 as variables. We noted that the OA risk-conferring
haplotype of these SNPs resulted in increased expression
relative to the non-risk haplotype, with and without DMR
methylation. This is a key observation as it highlights that these
two polymorphisms have both genetic and epigenetic effects on
the activity of the DMR. It also implies that the common OA-
associated SNPs at the SUPT3H/RUNX2 locus may be acting in
concert to modulate OA risk.
A search of the GTEx portal (18) reveals that there are at
least 10 tissues in which SUPT3H eQTLs have been reported that
correlate with rs10948172 genotype. These are present in a range
of tissues including brain, tibial nerve, testis and spleen. In each
case, the OA risk-conferring G allele correlates with higher levels
of SUPT3H expression, a pattern that we observed in OA joint
tissues. As far as we are aware, there are no previous reports of
the RUNX2 eQTL detected in this study, indicating that this effect
may be specific to certain tissues of the articulating joint.
In our meQTL analysis, we noted that the methylation
expression effect was only present for RUNX2. This, combined
with the fact that deletion of the DMR altered RUNX2 but not
SUPT3H expression, leads us to conclude that RUNX2 is the
principal target of regulation by the DMR. The meQTL was
identified at six CpG sites within the DMR (CpG7–12). All of these
CpG sites fall within the binding site of transcription factor
NFATC1, with three of these CpGs (CpG10–12) also being located
within the binding site of transcription factors BCL3, PBX3
and TCF3. This potentially highlights NFATC1, a protein that
has previously been linked to OA pathophysiology (23), as the
primary transcription factor operating at the SUPT3H/RUNX2-
DMR.
Genetic effects are operating at this locus in association with
SUPT3H. A potential role for this histone remodelling complex
subunit in the progression of OA still remains, yet the underly-
ing mechanism is unclear. The RUNX2 transcription factor has
been extensively studied in humans and in animal models. It is
essential for skeletogenesis and osteoblast differentiation, with
knockout mice lacking endochondral ossification (24). Further-
more, an increase in RUNX2 expression has beenwell established
in OA cartilage, where the transcription factor is associated with
chondrocyte hypertrophy and an increase in expression of the
collagenase MMP13 (25–27). In a recent study, it was reported
that deletion of the gene attenuates the progression of surgi-
cally induced OA in mice (28). Comprehensive knowledge of the
regulation of RUNX2 is therefore crucial to understanding both
normal and pathological development and maintenance of the
skeletal system.
In summary, we have undertaken a detailed characterization
of the SUPT3H/RUNX2-DMR and established that it is a novel
regulator of gene expression. Common polymorphisms that are
associatedwith OA correlate with differential methylation of the
DMR and altered expression of RUNX2. We propose that this is
the likely mechanism by which the OA association signal at this
locus operates. This opens the opportunity for further investiga-
tion, including potential intervention, by epigenetic modulation
of the DMR to fine-tune RUNX2 expression.
Materials and Methods
Patients
Tissue samples were obtained with informed consent from
patients undergoing elective total joint replacement surgery
for primary hip or knee OA, as described previously (29).
Ethical approval was granted by the Newcastle and North
Tyneside Research Ethics Committee (REC reference number
14/NE/1212). In total, we collected and analysed tissue samples
from a total of 260 patients. Further details are outlined in
Supplementary Table S2.
Tissue was processed as previously described (30). Nucleic
acids were extracted from cartilage and trabecular bone samples
using TRIzol reagent (Life Technologies) and from synovium
and infrapatellar fat pad using the EZNA DNA/RNA Isolation kit
(Omega Bio-Tek) according to the manufacturers’ instructions.
For genotyping and AEI analysis, DNA was used directly. For
methylation analysis, 500 ng DNA was bisulphite converted
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Figure 6. Correlation between AEI at RUNX2 andmethylation at the SUPT3H/RUNX2-DMR. Normalized cDNA allelic ratios of RUNX2 expression in synoviumwere plotted
against the respective DNA methylation values at CpG2 through to CpG12. P-values were calculated by linear regression analysis. n, the number of patients analysed
per CpG.
Figure 7. In vitro modulation of the SUPT3H/RUNX2-DMR. (A) CRISPR-Cas9 deletion of the DMR in the chondrocyte cell line Tc28a2 (TSS). Expression of SUPT3H, RUNX2
ALL (both isoforms) and RUNX2 P1 (long isoform) was measured by RT-qPCR. The graph represents the mean (+/− SEM) fold change of each gene/isoform following
deletion of the DMR (−DMR) compared to control cells without deletion (+DMR). Each bar represents six biological repeat experiments. Statistical significance was
determined by two-way ANOVA. **, P < 0.005; ns, not significant, P > 0.05. (B) Luciferase reporter analysis of DMR methylation in the chondrosarcoma cell line SW1353.
Mean luciferase activity (21 technical repeats) of the DMRnormalized against a control empty non-methylated or emptymethylated vector. E is the empty vector control.
CT denotes the non-risk conferring haplotype at rs62435998-rs62435999. TG denotes the risk-conferring haplotype at s62435998-rs62435999. Error bars represent the
SEM. P-values were calculated using a Mann–Whitney two-tailed exact test and are compared to the relevant non-methylated or methylated empty vector control,
unless otherwise indicated. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
using the EZ DNA methylation kit (Zymo Research). RNA was
quantified by Nanodrop (Thermo Fisher) and 1 μg (250 ng/μl)
was treated with Turbo DNase (Thermo Fisher) prior to a
20 μl reverse transcription reactionwith SuperScript First-Strand
cDNA synthesis kit (Invitrogen). The cDNA product was then
used for AEI and quantitative real-time PCR (RT-qPCR) analysis.
Genotyping
Genotyping at rs10948172 was completed by pyrosequencing at
proxy SNP rs529125 (r2=1.0). rs10948155 was genotyped directly
by pyrosequencing. Genotype at rs62435998 was determined
by a restriction fragment length polymorphism (RFLP) assay
using the enzyme HaeIII, which cuts at the C allele of the
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SNP. Both pyrosequencing RFLP analysis were carried out in
patient DNA samples following polymerase chain reaction (PCR)
amplification of the region encompassing the SNP (Table S2).
For pyrosequencing, PCR products were analysed using the
PyroMark Q24 Advanced platform (Qiagen) alongwith the appro-
priate sequencing primer (Table S3) and the manufacturer’s
recommended reagents.
Methylation analysis
DNA methylation was quantified by pyrosequencing. Assays
were designed to target specific CpG sites of interest using the
PyroMark Assay Design Software (Qiagen). Eight assays were
designed that each captured between 1 and 3 CpGs, with a total
of 15 CpGs analysed (Table S3). These included the four positive
CpGs from our 450k array analysis (cg13979708, cg19254793,
cg20913747 and cg18551225; CpGs 7–10 in Table S1). Pyrose-
quencing was performed using the PyroMark Q24 platform as
described previously (9). To determine the effect of genotype at
the SNPs of interest upon methylation, we constructed a linear
model of the percentage methylation at individual CpG sites,
assessing the relative contribution of each SNP using the log
worth and incremental R2 statistics. To visualize the SNPs most
closely associated with methylation at a given site, the incre-
mental improvement in R2 values capturing explained variability
was expressed as a percentage effect and plotted as a heat map,
both for the individual SNP data and for all of the SNPs combined.
Statistical analyses were performed with the aid of SAS JMP
Statistical Data Visualization Software.
AEI
AEI was used to determine the presence of rs10948172 eQTLs
for SUPT3H and RUNX2. Using a transcript SNP for each gene,
pyrosequencing was used to determine the percentage of each
allele in DNA and RNA, as described previously (31). For SUPT3H,
we used rs529125 (T/C), which is in perfect LD with rs10948172;
the OA risk-conferring G allele of rs10948172 corresponds to
the C allele of rs529125. There are no RUNX2 transcript SNPs
in LD with rs10948172 and we therefore selected an SNP with
a high minor allele frequency (MAF) to enable us to identify
compound heterozygotes. We chose rs1200428 (G/T, MAF = 0.23;
r2 = 0.005 with rs10948172). Due to the lack of LD between
rs1200428 and rs10948172, normalized heterozygote allelic ratios
were calculated and stratified by rs10948172 genotype as pre-
viously described (32,33). The PCR and sequencing primers are
listed in Table S4. For each cDNA and DNA sample, PCR reactions
were formed in triplicate, with samples being excluded from the
analysis if the values between the PCR replicates differed by>5%.
CRISPR-Cas9
Guide RNA (gRNA) sequences targeting upstream (5′CAAAA
CTTCTAGTCCCTAGA3′) and downstream (5′GAGACCGCGCCACA
GGAGGA3′) of the SUPT3H/RUNX2-DMR were designed using
the Optimized CRISPR Design Tool (crispr.mit.edu/). Single-
stranded DNA oligonucleotides (Sigma Aldrich) containing the
desired gRNA sequence along with the BbsI recognition motif
were annealed with the reverse complementary strand (95◦C–
25◦C, -6◦C/min). The double-stranded DNA oligonucleotides
were then ligated into the BbsI linearized CRISPR-Cas9 vector,
PX462, using T4 ligase (Invitrogen) overnight at 16◦C. Cells
from the human chondrocyte cell line Tc28a2 were grown in
monolayer culture as previously described (34) to 70–80% con-
fluence. For nucleofection, 106 cells per biological replicate were
incubated with 5 μg of plasmid DNA using the manufacturer-
recommended Cell Line 4D-Nucleofector X Kit in combination
with the 4D-Nucleofector System (Lonza).
Following nucleofection, cell monolayers were grown in each
well of a six well plate and nucleofected cells were selected
with puromycin after 24 h. Following expansion of cells into
T25 culture flasks, nucleic acids were extracted using the EZNA
DNA/RNA Isolation kit (Omega Bio-Tek) according to the manu-
facturer’s protocol. Deletion of the target region was confirmed
and quantified using endpoint PCR and Sanger sequencing.
Quantitative gene expression
Gene expression was quantified using TaqMan chemistry. Pre-
designed TaqMan assays (Integrated DNA Technologies) were
used to measure the expression of the target genes SUPT3H
(Hs.PT.58.3510503) and RUNX2. For RUNX2, two assays were
used: one targeting exons 6–7, measuring both the isoforms
of the gene (Hs.PT.56a.19568141, termed RUNX2 ALL) and one
targeting exons 1–2, therefore only detecting the P1 isoform
(Hs.PT.56a.23056352.g). It was not possible to measure the
expression of the P2 isoform alone due to the sequence identity
between the short isoform and exons 3–8. Expression was
assessed relative to the expression of three housekeeping genes:
18S, GAPDH and HPRT1 using the 2-ct method as previously
described (9).
Luciferase reporter assays
A 654 bp region (chr6:44,695,068-44,695,721; hg19) containing the
SUPT3H/RUNX2-DMR was cloned into the multiple cloning site
of the CpG-free luciferase vector, pCpGL (InvivoGen) using
the PstI and BamHI restriction sites (forward primer: 5′GGGG
CTGCAGAGCTTCAAAACAGGAAAACCAAG3′; reverse primer:
5′GGGGCCATGGCACTGTTGAGCAAATCATCAGG3′). The region
was amplified from a pool of genomic blood DNA and colonies
were isolated and Sanger sequenced to identify clones with the
major (CT) haplotype and clones with the minor (TG) haplotype
of rs62435998-rs62435999. Plasmids were in vitro methylated
using M.SssI (NEB) as previously described (35) and complete
methylation was confirmed by HpaII restriction digest. For each
well of a 96 well plate, 6000 cells from the chondrosarcoma cell
line SW1353 were seeded 24 h prior to transfection. Cells were
transfected with the relevant pCpGL luciferase vector construct
(100 ng) and pRL-TK Renilla vector (1.5 ng) using Fugene HD
transfection reagent (Promega) according to the manufacturer’s
protocol. After 24 h, cells were lysed and luciferase reporter
assays were performed (29).
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